Suspected piperacillin‐tazobactam induced nephrotoxicity in the pediatric oncology population. Issue 2 (30th August 2013)

• Record Type: Journal Article
• Authors: Pratt, Jennifer A.; Stricherz, Melisa K.; Verghese, Priya S.; Burke, Michael J.
• Is Part Of: Pediatric blood & cancer. Volume 61:Issue 2(2014:Feb.)
• Page Start: 366
• Page End: 368
• Publication Date: 2013-08-30
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.24720
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24720-sec-0001" sec-type="section"> <p>Neutropenic fever is a common complication of myelosuppressive therapy in pediatric oncology patients. Piperacillin‐tazobactam (PIP/TAZO) is a broad spectrum antibiotic used for empiric treatment of neutropenic fever. We describe four cases of suspected PIP/TAZO induced nephrotoxicity occurring in children with pediatric malignancies admitted to the hospital and treated for fever ± neutropenia. All patients exhibited acute renal injury shortly after PIP/TAZO administration with one of these cases having biopsy evidence of acute interstitial nephritis. These findings are suggestive of PIP/TAZO induced nephrotoxicity in pediatric oncology patients with fever ± neutropenia and that PIP/TAZO should be used judiciously in this population. Pediatr Blood Cancer 2014;61:366–368. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>